Making a CDI Department Better Through Intelligent Solutions from Iodine Software.

 

In the fast-paced world of healthcare, the quest for efficiency and accuracy is paramount. The adoption of innovative AI Healthcare software, particularly in Clinical Documentation Integrity (CDI), is transforming how healthcare professionals navigate patient records and identify opportunities for improved care. The stakes are high, as effective CDI can enhance patient outcomes, streamline workflows, and maximize revenue. One Black Book Market survey found nearly 90% of hospitals utilizing CDI solutions earned at least $1.5 million in additional healthcare revenue and claims reimbursement.

But what does the transition to a digital CDI process look like? What benefits and challenges does it bring, and how can it change the day-to-day work of healthcare professionals?

When Sheila Duhon, Director of Clinical Documentation Integrity at Steward Healthcare, first joined Steward, she sought a CDI solutions partner in Iodine Software. She shared her journey of integrating Iodine Software into her new role.

Duhon touches on several insights from her experience with Iodine, including:

  • The challenge of manual CDI review before Steward implemented Iodine Software,
  • The quick and efficient rollout of Iodine Software, with a dedicated team providing hands-on support to Steward Healthcare CDI specialists
  • The positive and collaborative experiences with Iodine’s team, from educators to client success managers to tech personnel

Guest Sheila Duhon, with a background in critical care, brings a wealth of experience and a unique perspective to the conversation. As the Director of Clinical Documentation Integrity at Steward Healthcare, she has played an instrumental role in the digital transformation of CDI practices at the institution. Her dedication to leveraging technology to improve patient care makes her a pioneering figure in the healthcare sector.

Recent Episodes

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…